NRX Pharmaceuticals, Inc. (NRXP): Nasdaq/NYSE listing notice — NRx Pharmaceuticals Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting; Sets 2025 Meeting

NRX Pharmaceuticals, Inc.

Received Nasdaq letter on Jan 12, 2026 for failing to hold annual meeting within 12 months of fiscal year end.
Company has 45 days to submit a plan to regain compliance; Nasdaq may grant exception until June 29, 2026.
Annual meeting set for March 23, 2026 with record date of February 12, 2026.
Stock continues trading under symbol NRXP; non-compliance indicator will be broadcast after five business days.
Stockholder proposals or director nominations must be received by January 26, 2026.

item 3.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(b)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5810(b)

Exact text from the filing

assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules. In accordance with Nasdaq Listing Rule 5810(b), the Company is required to disclose the receipt of the Nasdaq Letter. The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, which will continue to trade under the symbol “NRXP.” However, beginning five business days from the date of the

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-001455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.